Related Experiment Video

Updated: Mar 31, 2026

Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model
12:37

Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model

Published on: September 7, 2013

18.9K

The melanocortin receptors as targets for general obesity: contextualizing clinical failures and analyzing future

Claudia R Prindle1, Thomas L Bennett1, Benjamin H Rajewski1

  • 1Endevica Bio, Northbrook, IL, United States.

Frontiers in Endocrinology
|March 30, 2026
PubMed

Insights

The melanocortin system shows promise for obesity treatment. Recent research highlights modulating melanocortin-3 and -4 receptors for better weight loss and fewer side effects.

Area of Science:

  • Pharmacology
  • Endocrinology
  • Metabolic Diseases

Background:

  • The melanocortin system, particularly the melanocortin-4 receptor, is a well-established target for obesity treatment.
  • Past pharmaceutical efforts focused on melanocortin-4 receptor agonists for general obesity, but faced challenges with efficacy and side effects.

Purpose of the Study:

  • To review past clinical attempts at obesity treatment using melanocortin receptor agonists.
  • To compare historical approaches with current drug development programs.
  • To identify shortcomings of previous therapies to guide future novel melanocortin therapeutics.

Main Methods:

  • Review of existing scientific literature and clinical trial data.
  • Analysis of the efficacy, potency, selectivity, and side effect profiles of past melanocortin-4 receptor agonists.
  • Comparison of historical clinical outcomes with emerging strategies targeting multiple melanocortin receptors.

Main Results:

  • Numerous melanocortin-4 receptor agonists failed to achieve significant weight loss in clinical trials.
  • Challenges included insufficient potency, lack of selectivity, and unacceptable side effect profiles.
  • Emerging evidence suggests dual modulation of melanocortin-3 and -4 receptors may improve outcomes and mitigate side effects.

Conclusions:

  • Past clinical failures underscore the complexity of targeting the melanocortin system for obesity.
  • Novel therapeutic strategies should consider modulating both melanocortin-3 and -4 receptors.
  • Understanding historical limitations is crucial for developing effective future melanocortin-based obesity treatments.
Keywords:
food intakemelanocortin (MC)melanocortin-3 receptormelanocortin-4 receptormelanocortin-4 receptor agonistmetabolismobesityweight loss

More Related Videos

Measurement of Basal and Forskolin-stimulated Lipolysis in Inguinal Adipose Fat Pads07:59

Measurement of Basal and Forskolin-stimulated Lipolysis in Inguinal Adipose Fat Pads

Published on: July 21, 2017

10.2K
Encapsulation Thermogenic Preadipocytes for Transplantation into Adipose Tissue Depots08:30

Encapsulation Thermogenic Preadipocytes for Transplantation into Adipose Tissue Depots

Published on: June 2, 2015

9.9K

Related Concept Videos

Regulation of Food Intake01:30

Regulation of Food Intake

Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
3.1K
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
19.6K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.9K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68